Send us a text

Welcome to this week's episode of the Multiple Sclerosis Weekly Update, where we cover the most recent and impactful news related to MS. This week, we delve into a groundbreaking study that reveals a genetic variant influencing the severity and progression of MS in certain patients. We also unpack a legal dispute between Biogen and Novartis over the biosimilar of Tysabri and explore what this means for branded biologic-drug makers. Additionally, we discuss the surprising impact of myelin on axons in MS, compare the efficacy of rituximab and ocrelizumab, and reflect on Christina Applegate's journey with MS. Stay tuned for these stories and more in this week's episode.
Here are the like to the articles:
https://www.healthline.com/health-news/ms-symptoms-progress-more-quickly-in-certain-people-researchers-think-they-know-why
https://news.bloomberglaw.com/health-law-and-business/details-emerge-in-biogens-failure-to-block-biosimliar-tysabri
https://www.news-medical.net/news/20230630/Myelin-can-be-harmful-to-axons-in-multiple-sclerosis.aspx
https://www.physiciansweekly.com/comparing-the-efficacy-of-rituximab-and-ocrelizumab-for-relapsing-remitting-multiple-sclerosis/
https://www.sportskeeda.com/health-and-fitness/news-david-faustino-speaks-christina-applegate-s-struggle-multiple-sclerosis-diagnosis

The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments.
www.justmultiplesclerosis.com